首页> 外文OA文献 >PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)

【2h】

PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)

机译：患有曲妥珠单抗（TZ）耐药性ERBB2 +转移性乳腺癌（MBC）且早期化学疗法（CT）暴露受限的女性中ERBB2靶向治疗的PCN71成本效益（CE）分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Delea T; Sofrygin O; Tappenden P; Browning D; Amonkar MM; Karnon J; Lykopoulos K;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. 2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective [J] . T.E.Delea, P.Tappenden, O.Sofrygin, European Journal of Cancer Supplements . 2007,第4期

机译：2135事前对英国（UK）国家卫生署接受过曲妥珠单抗（TZ）治疗的ErbB2 +（HER2 +）转移性乳腺癌（MBC）妇女的拉帕替尼联合卡培他滨（L + C）的成本效益（CE）（NHS）观点
2. Pharmacokinetics (PK) and exposure-response (E-R) analysis of Kadcyla (K) as a single agent or in combination with Perjeta (P) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease [J] . Lu Dan, Li Chunze, Polhamus Daniel, Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：Kadcyla（K）作为单药或与Perjeta（P）结合使用对患有以下疾病的人类表皮生长因子受体2阳性（HER2 +）转移性乳腺癌（MBC）患者的药代动力学（PK）和暴露反应（ER）分析尚未接受过转移性疾病的化疗
3. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab [J] . Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, The European Journal of Health Economics . 2012,第5期

机译：拉帕替尼联合卡培他滨治疗已接受曲妥珠单抗治疗的HER2 +转移性乳腺癌女性的成本效益
4. Correlations between depressive symptoms and quality of life in metastatic breast cancer patients during chemotherapy [C] . Dragomir B.I., Campean A. European Association of Psychosomatic Medicine., Annual Meeting. . 2014

机译：化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
5. Investigating age varying effect of access to cancer care on immediate choice of chemotherapy among elderly women with metastatic breast cancer. [D] . Wan, Shaowei. 2010

机译：调查在转移性乳腺癌的老年妇女中，癌症治疗对立即选择化疗的年龄差异影响。
6. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [O] . José Baselga, Karen A. Gelmon, Shailendra Verma, -1

机译：在先前的曲妥珠单抗治疗期间进展的人类表皮生长因子受体2-阳性转移性乳腺癌患者中帕妥珠单抗和曲妥珠单抗的II期试验
7. PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY) [O] . Sofrygin O, Delea T, Tappenden P, 2008

机译：PCN9比例风险（PH）威布尔模型在分析曲妥珠单抗（TZ）耐药性ERBB2 +（HER2 +）转移性乳腺癌（MBC）患儿的无进展生存率（PFS）和总生存率（OS）方面的有效性C）仅卡西他滨（仅C）

PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)

著录项

相似文献

相关主题

期刊订阅